Tracy Kelley
Family · Wilmington, OHNPI 1851943757
Payments from drug & device makers
Across 580 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AbbVie$1K
- Amneal Pharmaceuticals LLC$888
- MDD US Operations, LLC$845
- Biohaven Pharmaceutical Holding Company Ltd.$455
- Neurocrine Biosciences, Inc.$442
- plus $4K from 33 others
What the payments were for
- Travel & lodging$1,72217%
- Food & beverage$8,27083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$1,713
- AIMOVIG$122
- UBRELVY$122
- NURTEC ODT$116
How this compares
$9,992 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 63 | $499,326 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $170,343 |
| Austedo XrDeutetrabenazine | 29 | $163,617 |
| Nurtec OdtRimegepant Sulfate | 114 | $144,351 |
| AustedoDeutetrabenazine | 24 | $114,640 |
| XcopriCenobamate | 96 | $110,694 |
| EpidiolexCannabidiol (Cbd) | 14 | $97,543 |
| UbrelvyUbrogepant | 38 | $63,421 |
| Aimovig AutoinjectorErenumab-Aooe | 77 | $62,064 |
| NuplazidPimavanserin Tartrate | 11 | $53,670 |
| QuliptaAtogepant | 45 | $47,936 |
| LamictalLamotrigine | 26 | $37,358 |
| Emgality PenGalcanezumab-Gnlm | 32 | $23,651 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $22,381 |
| AptiomEslicarbazepine Acetate | 15 | $22,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $442 | $499,32663 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $206 | $278,25653 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $34 | $170,34312 claims |
| PfizerNurtec Odt, Zavzpret | $389 | $164,700133 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $1,410 | $123,412113 claims |
| SK Life Science, Inc.Xcopri | $255 | $110,69496 claims |
| Acadia Pharmaceuticals IncNuplazid | $105 | $53,67011 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $48 | $22,38119 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $119 | $22,14615 claims |
| UCB, Inc.Briviact | $86 | $20,51620 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $40 | $18,40723 claims |
| Lilly USA, LLCMounjaro | $392 | $14,24013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Wilmington
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.